Guggenheim Maintains Buy on Foghorn Therapeutics, Sets $5 Target
Guggenheim reiterated a Buy rating on Foghorn Therapeutics's stock, setting a price target of $5.00. This target represents a potential upside of 71.2% from the stock's closing price of $2.92 on October 1.